Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$4.84 USD
-0.14 (-2.81%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $4.86 +0.02 (0.41%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Black Diamond Therapeutics, Inc. [BDTX]
Reports for Purchase
Showing records 81 - 89 ( 89 total )
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Initiating with an OUTPERFORM and $45 PT: Carving Through Cancer
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Brain Cancer Development Candidate Nominated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189 Phase 1 Data Slated for ASCO 2021; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189''s Selectivity Index Positions It as a Potential Best-in-Class Agent, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189 Receives Fast Track Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
ASCO Updates - We''re Keeping a Close Eye on Amivantamab and Enhertu; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Competitive Landscape Updates at ASCO 2020; 1Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Breaking the Mold in Precision Oncology; Initiating at Buy and $53 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R